ChemoCentryx

January 31, 2019

New Plans Announced for Full Marketing Approval of Avacopan as Treatment for ANCA Vasculitis

News

In light of upcoming Phase 3 data, ChemoCentryx and Vifor Fresenius Medical Care Renal Pharma have decided not to pursue the conditional approval of avacopan in Europe for patients with ANCA-associated ... Read more

April 17, 2018

Avacopan Safer, More Effective than Standard Therapy in AAV Patients, Phase 2 Trials Show

News

Patients with ANCA-associated vasculitis (AAV) have fewer adverse events and better quality of life when treated with avacopan over standard therapy, results from two Phase 2 clinical trials show. ... Read more

January 9, 2018

EMA Accepts Conditional Application for ANCA Treatment Avacopan

News

The European Medicines Agency (EMA) has accepted for review ChemoCentryx’s application to approve Avacopan (CCX168) as a treatment for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The company, with its partner ... Read more

November 14, 2017November 14, 2017

ChemoCentryx Making Progress Recruiting Patients for Phase 3 Trial of ANCA-Associated Vasculitis Therapy

News

ChemoCentryx has enrolled 30 percent of the 300 ANCA-associated vasculitis patients it hopes to recruit for a Phase 3 trial assessing the effectiveness of its therapy avacopan. The company is ... Read more

August 22, 2017

Phase 3 Trial of Avacopan in ANCA-associated Vasculitis Patients Is Now Enrolling

News

The Phase 3 ADVOCATE trial, evaluating ChemoCentryx‘s investigational drug avacopan (formerly CCX168) for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is now enrolling participants. The update is part of ... Read more

Pin It on Pinterest